

Who can take part?

You or someone you care for may be able to take part if you/they:

- ▲ are 12 years of age or older
- have been diagnosed with moderate to severe atopic dermatitis
- ▲ have symptoms even with using creams or lotions.

What else do I need to consider?

- ▲ The study team will explain the possible benefits and risks of the study.
- ▲ You do not have to take part in the study if you don't want to.
- ▲ If you choose to take part in the study, you can stop participating at any time.
- You will not be paid to take part in this study, but you will be reimbursed for reasonable travel costs during your participation.
- ▲ All study medications and study-related tests will be provided at no cost to you.
- ▲ A team of doctors and nurses will monitor your health carefully during the study.



How do I get more information?

To find out more, contact the study team using the information provided here. Study participation is voluntary. By contacting us, you are under no obligation to take part in the study.



Participant Information

This brochure contains information about the HILLIER Study for people with moderate to severe atopic dermatitis (AD). This information should help you decide whether you or someone you know may want to take part in the study.

Participant Brochure, 01 Dec 2020 [V02 AUS(en)02]

What is a clinical research study?

A clinical research study is a medical study that helps to answer important questions about an investigational medication, such as:

- Does it work?
- ▲ What amount, or dose, may work best?
- ▲ How safe is it?
- Are there side effects?

All medications must be tested in clinical research studies before they can be approved to prescribe to participants. Without people taking part in these studies, we would have no new medications.

Deciding to take part in a clinical research study is your decision. If you have any questions, you can contact the study team using the information provided in this brochure.

About the HILLIER Study

The HILLIER Study is being carried out to learn more about whether the study drug works, and how safe it is for people with moderate to severe AD.

Why is the HILLIER Study important?

The study is being done because treatment options for AD are limited. The study drug has been approved in more than 50 countries for treating severe asthma, and will now be studied in AD.

What will the HILLIER Study involve?

If you take part, you will be in the HILLIER Study for up to 1 year and 3 months. You will need to:

- ▲ attend study centre visits every 4 weeks to receive an injection of study drug or placebo (an injection without the active ingredient)
- ▲ complete a daily diary of your symptoms.

The study is made up of 4 periods.

Screening period (up to 4 weeks)

You will visit the study centre to see if the study is suitable for you and whether you want to take part.



In case of study disruption, if you cannot

a healthcare professional visit you at home,

or a telemedicine visit by phone or video.

visit the study centre, you may have



First study dosing period (16 weeks)

You will visit the study centre 5 times for study assessments. Half of the participants will receive placebo and half will receive the study drug once every 4 weeks. You may continue to use your regular moisturizer.





Second study dosing period (36 weeks)

You will visit the study centre 9 times (once every 4 weeks) for study assessments. You will either receive the study drug at each visit **OR** at every other visit, alternating with placebo. This means you will receive an injection at each visit. You may continue to use your regular moisturizer.

Follow-up period (8 weeks)

You will visit the study centre once for study assessments after you have received the last dose of study drug.

